These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21298595)

  • 1. [Safety of drug therapy].
    Kornhuber J; Mühlbacher M
    Fortschr Neurol Psychiatr; 2011 Feb; 79(2):71-2. PubMed ID: 21298595
    [No Abstract]   [Full Text] [Related]  

  • 2. Beware of new drugs, study suggests.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 May; 13(10):1-2, 5. PubMed ID: 12492085
    [No Abstract]   [Full Text] [Related]  

  • 3. Study dispels assumptions about adverse drug events.
    Rollins G
    Rep Med Guidel Outcomes Res; 2001 Aug; 12(17):1-2, 5. PubMed ID: 12296363
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse drug reactions among inpatients in a north Indian referral hospital.
    Uppal R; Jhaj R; Malhotra S
    Natl Med J India; 2000; 13(1):16-8. PubMed ID: 10743370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low quality of reporting adverse drug reactions in paediatric randomised controlled trials.
    de Vries TW; van Roon EN
    Arch Dis Child; 2010 Dec; 95(12):1023-6. PubMed ID: 20551194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.
    Blenkinsopp A; Wilkie P; Wang M; Routledge PA
    Br J Clin Pharmacol; 2007 Feb; 63(2):148-56. PubMed ID: 17274788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pharmacy-based concurrent surveillance and medical record retrospective reporting of adverse drug reactions.
    Schumock GT; Thornton JP; Witte KW
    Am J Hosp Pharm; 1991 Sep; 48(9):1974-6. PubMed ID: 1928145
    [No Abstract]   [Full Text] [Related]  

  • 8. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
    Grandinetti CA; Osborne SF
    Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug safety--important to us all!
    Böttiger LE
    J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
    [No Abstract]   [Full Text] [Related]  

  • 10. The science of health technology assessment: the safety perspective.
    Shear NH
    Can J Clin Pharmacol; 2001; 8 Suppl A():24A-28A. PubMed ID: 11586375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing drug safety.
    Moore N
    BMJ; 2005 Mar; 330(7490):539-40. PubMed ID: 15746143
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacovigilance: theoretical and practical aspects].
    Paoletti V; Galeotta G; Mammarella A
    Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G; Pariente A; Coloma PM; Kors JA; Polimeni G; Miremont-Salamé G; Catania MA; Salvo F; David A; Moore N; Caputi AP; Sturkenboom M; Molokhia M; Hippisley-Cox J; Acedo CD; van der Lei J; Fourrier-Reglat A;
    Pharmacoepidemiol Drug Saf; 2009 Dec; 18(12):1176-84. PubMed ID: 19757412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):529-44. PubMed ID: 12426939
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):117-32. PubMed ID: 14998074
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacoepidemiology and drug safety.
    Pharmacoepidemiol Drug Saf; 2001; 10(5):467-82. PubMed ID: 11802594
    [No Abstract]   [Full Text] [Related]  

  • 17. Meta-analysis and adverse drug reactions.
    Mittmann N; Liu BA; Knowles SR; Shear NH
    CMAJ; 1999 Apr; 160(7):987-8. PubMed ID: 10207335
    [No Abstract]   [Full Text] [Related]  

  • 18. Points to consider: the roles of surveillance and epidemiology in advancing drug safety.
    Edwards R; Faich G; Tilson H;
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):665-7. PubMed ID: 15719353
    [No Abstract]   [Full Text] [Related]  

  • 19. [The Medical Products Agency suggests improved drug safety follow-ups. New grasps of better knowledge and adverse effects reporting].
    Sjölin-Forsberg G; Lindeskog B; Lundqvist KM; Feltelius N; Alvan G
    Lakartidningen; 2007 Apr 18-24; 104(16):1226-9. PubMed ID: 17536352
    [No Abstract]   [Full Text] [Related]  

  • 20. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.